Pharma Pioneer

Promising Early Results: Deltacel-01 Trial Stabilizes Lung Tumor and Clears Brain Metastases in Patient Two

19 May 2024
3 min read

Kiromic BioPharma, Inc., a clinical-stage biotherapeutics firm, has announced positive initial findings from its Deltacel-01 Phase 1 clinical study. The trial is assessing the efficacy of Deltacel™ (KB-GDT-01), an allogeneic, readily available Gamma Delta T-cell (GDT) therapy for patients with stage 4 metastatic non-small cell lung cancer (NSCLC). Early data indicates that the treatment has successfully stabilized the primary lung tumor and eliminated brain metastases in the second patient enrolled in the study. The treatment's safety and tolerability were also deemed favorable, with stable disease status confirmed via CT scan. Notably, metastatic disease observed in an MRI scan before the treatment was completely resolved in a follow-up MRI conducted six weeks into the treatment. The patient is undergoing treatment at the Beverly Hills Cancer Center (BHCC).
Pietro Bersani, CEO of Kiromic BioPharma, highlighted the promising nature of the six-week outcomes, which, along with results from the first patient, reinforce the potential of Deltacel as a treatment for advanced-stage disease. The complete disappearance of brain metastases in the patient suggests the therapy's ability to cross the blood-brain barrier and contributes to the growing evidence of its benefits.
Afshin Eli Gabayan, M.D., Medical Oncologist and Principal Investigator at BHCC, echoed the optimism, emphasizing the importance of the preliminary results, particularly the absence of dose-limiting toxicities, and the commitment of the center to offering innovative care for patients with limited treatment options.
The company anticipates sharing initial safety, tolerability, and preliminary efficacy results from the third patient in the Deltacel-01 trial by the end of March. The open-label Phase 1 clinical trial involves administering two infusions of Deltacel combined with low-dose, localized radiation therapy over a 10-day period to patients with stage 4 NSCLC. The primary goal of the trial is to assess the safety of the treatment, with secondary objectives including measures of response and survival rates.
Deltacel (KB-GDT-01) is an experimental GDT therapy in the Phase 1 trial aimed at treating stage 4 metastatic NSCLC. It is an allogeneic product made up of unmodified donor-derived GDT cells and represents the leading candidate in Kiromic’s GDT platform. The therapy is designed to harness the natural potency of GDT cells against solid cancers, with an initial focus on NSCLC, which accounts for 80% to 85% of all lung cancer cases. Preclinical studies have shown a favorable safety and efficacy profile for Deltacel when used in conjunction with low-dose radiation.
The Beverly Hills Cancer Center is a private, academic, community-based facility that offers advanced cancer treatments, clinical trials, and research, attracting patients worldwide. It provides access to cutting-edge clinical trials and is staffed by a multidisciplinary team of medical professionals who deliver exceptional patient care and support services.
Kiromic BioPharma is leveraging its proprietary DIAMOND® AI 2.0 target discovery engine to develop cell therapies, focusing on immuno-oncology. The company is developing a multi-indication allogeneic cell therapy platform that targets solid tumors using the natural potency of Gamma Delta T-cells. Kiromic’s DIAMOND® AI aims to significantly reduce the time and cost associated with developing live drugs by integrating data science with target identification.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Jasper Initiates SPOTLIGHT Trial with First Patient Dosed for CIndU Treatment with Briquilimab
Pharma Pioneer
2 min read
Jasper Initiates SPOTLIGHT Trial with First Patient Dosed for CIndU Treatment with Briquilimab
19 May 2024
Biotechnology firm Jasper Therapeutics has initiated its Phase 1b/2a clinical trial, for the treatment of chronic inducible urticaria (CIndU) using a novel antibody, briquilimab.
Read →
Celularity Seeks FDA Orphan Drug Status for PDA-002 to Treat FSHD
Pharma Pioneer
2 min read
Celularity Seeks FDA Orphan Drug Status for PDA-002 to Treat FSHD
19 May 2024
Celularity Inc. has submitted an application to the U.S. Food and Drug Administration (FDA) for orphan drug designation for PDA-002, its placental-derived cell therapy.
Read →
23andMe Launches Phase 1 Trial for ULBP6-Targeted Dual-Action Antibody 23ME-01473
Pharma Pioneer
2 min read
23andMe Launches Phase 1 Trial for ULBP6-Targeted Dual-Action Antibody 23ME-01473
19 May 2024
A clinical trial has been initiated for an innovative drug candidate, 23ME-01473, developed by 23andMe Holding Co., a prominent entity in human genetics and biopharmaceuticals.
Read →
ACELYRIN Reports Positive Early-Stage Results for Lonigutamab in Treating Thyroid Eye Disease
Pharma Pioneer
3 min read
ACELYRIN Reports Positive Early-Stage Results for Lonigutamab in Treating Thyroid Eye Disease
19 May 2024
Significant advancements have been observed in the treatment of thyroid eye disease (TED) with lonigutamab, a humanized monoclonal antibody.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.